$6.24
0.182.97%
Last update: Jul 18, 5:20 PM
15 minutes delayed
Comments
Loading...
Syros Pharmaceuticals
SYRSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Syros Pharmaceuticals (NASDAQ:SYRS) Stock, Analyst Ratings, Price Targets, Forecasts
Syros Pharmaceuticals Inc has a consensus price target of $14.83 based on the ratings of 6 analysts. The high is $23 issued by Roth Capital on September 23, 2021. The low is $10 issued by Alliance Global Partners on May 17, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler on June 26, 2024, May 15, 2024, and April 3, 2024, respectively. With an average price target of $14.33 between HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler, there's an implied 129.70% upside for Syros Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
JMP Securities
Oppenheimer
Alliance Global Partners
1calculated from analyst ratings
Analyst Ratings for Syros Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2024 | Buy Now | 140.38% | HC Wainwright & Co. | Andrew Fein | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 140.38% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 108.33% | Piper Sandler | Edward Tenthoff | → $13 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 140.38% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 12.18% | Piper Sandler | Edward Tenthoff | $11 → $7 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 140.38% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 140.38% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 140.38% | JMP Securities | Jason Butler | $16 → $15 | Maintains | Market Outperform | Get Alert |
| 03/03/2023 | Buy Now | 108.33% | Oppenheimer | Mark Breidenbach | $15 → $13 | Maintains | Outperform | Get Alert |
| 03/03/2023 | Buy Now | 140.38% | HC Wainwright & Co. | Andrew Fein | → $15 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 220.51% | Piper Sandler | Edward Tenthoff | $27 → $20 | Maintains | Overweight | Get Alert |
| 11/15/2022 | Buy Now | 156.41% | JMP Securities | Jason Butler | $40 → $16 | Maintains | Market Outperform | Get Alert |
| 11/15/2022 | Buy Now | 140.38% | Oppenheimer | Mark Breidenbach | $30 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2022 | Buy Now | 220.51% | HC Wainwright & Co. | Andrew Fein | $6 → $20 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | -51.92% | Oppenheimer | Mark Breidenbach | $90 → $30 | Maintains | Outperform | Get Alert |
| 07/12/2022 | Buy Now | -3.85% | HC Wainwright & Co. | Andrew Fein | $100 → $60 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 60.26% | HC Wainwright & Co. | Andrew Fein | $150 → $100 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 60.26% | Alliance Global Partners | Matt Cross | $140 → $100 | Maintains | Buy | Get Alert |
| 09/23/2021 | Buy Now | 268.59% | Roth Capital | Zegbeh Jallah | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Syros Pharmaceuticals (SYRS) stock?
The latest price target for Syros Pharmaceuticals (NASDAQ:SYRS) was reported by HC Wainwright & Co. on June 26, 2024. The analyst firm set a price target for $15.00 expecting SYRS to rise to within 12 months (a possible 140.38% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Syros Pharmaceuticals (SYRS)?
The latest analyst rating for Syros Pharmaceuticals (NASDAQ:SYRS) was provided by HC Wainwright & Co., and Syros Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Syros Pharmaceuticals (SYRS)?
There is no last upgrade for Syros Pharmaceuticals
When was the last downgrade for Syros Pharmaceuticals (SYRS)?
There is no last downgrade for Syros Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Syros Pharmaceuticals (SYRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on June 26, 2024 so you should expect the next rating to be made available sometime around June 26, 2025.
Is the Analyst Rating Syros Pharmaceuticals (SYRS) correct?
While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a reiterated with a price target of $15.00 to $15.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $6.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.